Should we disclose amyloid imaging results to cognitively normal individuals?

被引：28

作者：

Grill, Joshua D. ^{[1
]}

Johnson, David K. ^{[2
]}

Burns, Jeffrey M. ^{[2
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Mary S Easton Ctr Alzheimers Dis Res, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA

[2] Univ Kansas, Alzheimers Dis Ctr, Lawrence, KS 66045 USA

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2013年 / 3卷 / 01期

关键词：

D O I：

10.2217/NMT.12.75

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Demonstration of brain accumulation of fibrillar amyloid-beta protein via PET with amyloid-specific ligands may support the diagnosis of Alzheimer's disease (AD). There is increasing recognition of the potential use of amyloid imaging to detect the pathology of AD in vivo in individuals with no ostensible cognitive impairment. Research use of amyloid PET in cognitively normal patients will be key to the pursuit of therapies able to delay cognitive impairment and dementia due to AD. We review the pros and cons of disclosing amyloid imaging results to cognitively normal individuals in clinical and research settings and provide draft recommendations.

引用

收藏

页码：43 / 51

页数：9

相关论文

共 68 条

[1]

Aizenstein HJ, ARCH NEUROL, V65, P1509

[2]

Alzheimer Research Forum, NEWS FOC 2012 HUM AM

[3] Amyloid load and cerebral atrophy in Alzheimer's disease:: An 11C-PIB positron emission tomography study [J].

Archer, Hilary A. ;

Edison, Paul ;

Brooks, David J. ;

Barnes, Jo ;

Frost, Chris ;

Yeatman, Toni ;

Fox, Nick C. ;

Rossor, Martin N. .

ANNALS OF NEUROLOGY, 2006, 60 (01) :145-147

[4] Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study [J].

Barthel, Henryk ;

Gertz, Hermann-Josef ;

Dresel, Stefan ;

Peters, Oliver ;

Bartenstein, Peter ;

Buerger, Katharina ;

Hiemeyer, Florian ;

Wittemer-Rump, Sabine M. ;

Seibyl, John ;

Reininger, Cornelia ;

Sabri, Osama .

LANCET NEUROLOGY, 2011, 10 (05) :424-435

[5]

Bayer-Carter JL, ARCH NEUROL, V68, P743

[6] Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly [J].

Becker, J. Alex ;

Hedden, Trey ;

Carmasin, Jeremy ;

Maye, Jacqueline ;

Rentz, Dorene M. ;

Putcha, Deepti ;

Fischl, Bruce ;

Greve, Douglas N. ;

Marshall, Gad A. ;

Salloway, Stephen ;

Marks, Donald ;

Buckner, Randy L. ;

Sperling, Reisa A. ;

Johnson, Keith A. .

ANNALS OF NEUROLOGY, 2011, 69 (06) :1032-1042

[7] Neuropathology of older persons without cognitive impairment from two community-based studies [J].

Bennett, D. A. ;

Schneider, J. A. ;

Arvanitakis, Z. ;

Kelly, J. F. ;

Aggarwal, N. T. ;

Shah, R. C. ;

Wilson, R. S. .

NEUROLOGY, 2006, 66 (12) :1837-1844

[8] β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia [J].

Bourgeat, P. ;

Chetelat, G. ;

Villemagne, V. L. ;

Fripp, J. ;

Raniga, P. ;

Pike, K. ;

Acosta, O. ;

Szoeke, C. ;

Ourselin, S. ;

Ames, D. ;

Ellis, K. A. ;

Martins, R. N. ;

Masters, C. L. ;

Rowe, C. C. ;

Salvado, O. ;

Grp, A. I. B. L. Res .

NEUROLOGY, 2010, 74 (02) :121-127

[9] Predicting positivity for a new era of Alzheimer disease prevention trials [J].

Burns, Jeffrey M. ;

Klunk, William E. .

NEUROLOGY, 2012, 79 (15) :1530-1531

[10]

Cairns NJ, ARCH NEUROL, V66, P1557

← 1 2 3 4 5 6 7 →